Bromodomain and extra-terminal (BET) family member proteins (BRD2, BRD3, BRD4 and
BRDT) play a pivotal role in interpreting the epigenetic information of histone Kac …

Castration-resistant prostate cancer (CRPC) presents significant challenges in clinical
management due to its resistance to conventional androgen receptor (AR)-targeting …

Abstract Treatment with androgen receptor pathway inhibitors (ARPIs) in prostate cancer
leads to the emergence of resistant tumors characterized by lineage plasticity and …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

Abstract Lysine-specific demethylase 1 (LSD1) is a histone demethylase that promotes
stemness and cell survival in cancers such as prostate cancer. Most prostate malignancies …

Background Genomic alterations in DNA damage response (DDR) genes are common in
metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic …

The androgen receptor (AR) signaling pathway is critical for growth and differentiation of
prostate cancer cells. For that reason, androgen deprivation therapy with medical or surgical …

Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-
induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (eg …

Prostate cancer is a major health issue in western countries and is the second leading
cause of cancer death in American men. Prostate cancer depends on the androgen receptor …

Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung
cancer, commonly have a poor prognosis and limited therapeutic options. We report that …